Analyst vs AI Verdict
Wall Street
AI Expert Panel
Price Chart
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 67.7% | 67.7% | 67.7% | 91.9% | 91.9% | 91.9% |
| P/E (TTM) | 21.57 | 31.35 | 36.69 | 38.05 | 38.20 | 36.54 |
| Net Margin | 15.0% | 18.7% | 18.7% | 18.4% | 18.4% | 18.4% |
| Gross Margin | 29.8% | 31.6% | 31.6% | 31.1% | 31.1% | 31.1% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 0.43 | 0.43 | 0.43 | 0.57 | 0.57 | 0.57 |
Company Summary
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
View full stock profile →Trade Outcome
Historical Stats
MEDP Bounce Up
Signal Info
Disclaimer: This is an automated trading signal generated by AI analysis. It is not financial advice. Always do your own research before making investment decisions. Past performance does not guarantee future results.